Navigation Links
Studies assess genetics, modified treatment to improve outcomes, reduce toxicity
Date:12/8/2012

(ATLANTA, December 8, 2012) Research identifying genetic factors that affect survival of patients with blood cancers and evaluating the effectiveness of modified treatment strategies to improve outcomes while reducing toxicity will be presented today at the 54th Annual Meeting of the American Society of Hematology (ASH).

While the cancer research community has seen many significant therapeutic advances over the last decade, only recently have investigators identified how patients' individual genetic makeup influences their short- and long-term response to therapy, demonstrating that while the disease may respond positively to therapy, the patient may not. Current studies take these insights a step further, examining specific patient subpopulations to determine their risk for negative outcomes and whether early preventive interventions or treatment adjustments may help avoid treatment-related toxicity.

"Data presented today offer important insights into how and why patients respond to blood cancer treatment," said William G. Woods, MD, moderator of the press conference, Pediatric Hematology/Oncology Director, and the Daniel P. Amos Children's Chair of the Aflac Cancer Center and Blood Disorders Service at Children's Healthcare of Atlanta. "Findings from these studies help further support the notion of one day personalizing cancer treatment to the individual, rather than to the disease, to improve survival and reduce toxicity."

This press conference will take place on Saturday, December 8, 2012, at 10:00 a.m. EST.

WT1 SNP rs16754 Genotype Predicts Treatment Related Mortality (TRM) in African-American and Asian Pediatric AML Patients: A Report From the Children's Oncology Group[Abstract 1385]

New research suggests that the presence of a specific genetic marker, known as WT1 SNP rs16754, may be associated with reduced
'/>"/>

Contact: Andrea Slesinski
aslesinski@hematology.org
614-352-5096
American Society of Hematology
Source:Eurekalert

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. John Theurer Cancer Center to present 37 studies at the 2012 ASH Annual Meeting
2. Benefit6 Whole Body Protection, a New Product by I Do Strive LLC, Provides Increased Energy Production According to Recent Studies
3. Sharp spike in computer-related injuries predicted for medical workers, find studies
4. Analysis of conflicting fish oil studies finds that omega-3 fatty acids still matter
5. Studies from 2012 Quality Care Symposium highlight findings in improving quality of cancer care
6. New studies show effects of mammography guideline changes
7. 2 NIH studies show power of epidemiology research; Underscore need to address health disparities
8. Scripps studies show community-based diabetes programs are key to lowered costs and improved care
9. Cancer Drug Reduced Relapses in MS Patients: Studies
10. University of Houston India Studies Program presents Circuits of Empire: India as Metropole
11. Studies Show Limits, Promise of Laser Removal of Tattoos
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... 26, 2014 Recently, Dylan Queen, a ... excitedly released its collection of discounted prom dresses, most ... a senior spokesman of the company, the promotion is ... promotion is to expand the UK market. , The ... different colors, lengths, and styles: A-line strapless, empire strapless ...
(Date:12/25/2014)... 2014 BambooFlooringChina.com sells many bamboo products ... flooring. Today, the company announces big discounts on ... and colors. , BambooFlooringChina.com is the world’s leader in ... is valid until Jan. 20, 2015. , The bamboo ... with a natural thread. All the bamboo strips for ...
(Date:12/25/2014)... updated its blog to provide professional shopping tips on wedding and ... LunaDress.co.uk come with big discounts, up to 80 percent off. , ... to be a most exciting memory and can show off a ... a wedding. On the updated fashion blog, ladies can now find ... day . , Going out with friends to a party is ...
(Date:12/25/2014)... 2014 (HealthDay News) -- Overeating is common during the holidays, ... moderation, an expert says. "Don,t arrive at a party ... you know you,ll be attending a party, but deprivation leads ... dietitian at Northern Westchester Hospital in Mount Kisco, N.Y., said ... healthy during the day and even to have a snack ...
(Date:12/25/2014)... AngelWeddingDress.com tries its best to translate the experience of ... has introduced its new collection of 2015 prom dresses, ... new prom outfits are guaranteed to contain the perfect ... specially designed for 2015. Anyone who wants to buy ... website before Jan. 26, 2015, the deadline of the ...
Breaking Medicine News(10 mins):Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... presented today at the annual meeting of the Radiological ... evidence of the benefit of annual screening ultrasound for ... for breast cancer. In addition, the study confirmed that ... "We found that annual screening with ultrasound in ...
... ... transplant center and the first for Chicago’s south and southwest suburbs, following formal approval ... Review Board. , ... Springfield, Ill. (Vocus) -- Advocate Christ Medical Center in Oak Lawn, Ill. ...
... ... announces that a new market research report ... The Future of Central Nervous System Diseases ... Benchmarking, Product Pipeline and Deals Analysis ...
... , NEW YORK, ... market research report is available in its catalogue: ... Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline ... , Summary , The author ...
... The Kerlan Jobe Orthopaedic Clinic, a sports medicine clinic in ... million to settle allegations that it received illegal kickbacks from ... , The settlement resolves allegations that HealthSouth paid ... grants, donations to the Kerlan Jobe Foundation, loan forgiveness on ...
... Ky., Dec. 1 A scientist who broadened the understanding ... control and relieve it -- has won the 2010 University ... professor emeritus at McGill University in Montreal, was selected for ... not at the point of injury but instead in their ...
Cached Medicine News:Health News:Annual screening with breast ultrasound or MRI could benefit some women 2Health News:State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 2Health News:State Approves Plans For Kidney Transplants At Advocate Christ Medical Center 3Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 13Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 14Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 15Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 16Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 17Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 18Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 19Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 20Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 21Health News:Reportlinker Adds The Future of Central Nervous System Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 22Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 4Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 5Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 6Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 7Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 8Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 9Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 10Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 11Health News:Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 12
(Date:12/24/2014)... SAN DIEGO , Dec. 24, 2014 /PRNewswire/ ... the West, developing the proprietary Natural Killer (NK) ... announces that Dr. Patrick Soon-Shiong , NantWorks ... into a definitive agreement to purchase approximately $48 ... In connection with the investment, he will be ...
(Date:12/24/2014)... , Dec. 23, 2014 Echo ... medical device company focused on skin permeation, continuous ... Scott W. Hollander has been appointed ... Hollander has more than 20 years of experience ... industries, and most recently served as Vice President, ...
(Date:12/24/2014)... Ohio , Dec. 23, 2014   ... treatment decision support to healthcare providers for behavioral ... it has secured $30 million in equity financing ... Virginia C. Drosos , President and Chief Executive ... clinical adoption and development of Assurex Health,s ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4
... 1, 2011 Novartis Pharmaceuticals Corporation ("Novartis") will showcase ... and investigational agents at the 47th Annual Meeting of ... underscore the company,s commitment to developing treatments to improve ... our commitment to R&D and collaborations with the scientific ...
... (Nasdaq: NBIX ) announced today that Kevin Gorman, ... presenting at the Jefferies 2011 Global Healthcare Conference in New ... on Tuesday, June 7, 2011 at 11:00 a.m. Eastern Time ... and may be accessed on the Company,s website at ...
Cached Medicine Technology:Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 2Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 3Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 4Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 5Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 6Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 7Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 8Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 9Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 10Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 11Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 12Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 13Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 14Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 15Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 16Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 17Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 18